Hamilton Capital LLC Takes Position in Abbott Laboratories $ABT

Key Points

• Hamilton Capital LLC acquired 48,474 Abbott shares worth approximately $4.4 million in the second quarter, making ABT its 16th-largest holding and 0.2% of its portfolio. Institutional investors and hedge funds collectively own 75.18% of the stock.
• Abbott reported quarterly adjusted earnings of $1.31 per share, beating estimates, while revenue rose 13% year over year to $12.59 billion. Management maintained 2026 earnings guidance of $5.45–$5.60 per share.
• Analysts maintain a broadly positive view, with a consensus rating of “Moderate Buy” and an average price target of $119.50. Abbott also pays a quarterly dividend of $0.63, equivalent to a 2.3% annualized yield.

Hamilton Capital LLC bought a new position in Abbott Laboratories (NYSE:ABT - Free Report) during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 48,474 shares of the healthcare product maker's stock, valued at approximately $4,399,000. Abbott Laboratories makes up 0.2% of Hamilton Capital LLC's portfolio, making the stock its 16th biggest holding.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of ABT. MidAtlantic Capital Management Inc. acquired a new stake in shares of Abbott Laboratories in the fourth quarter valued at $25,000. Cornerstone Financial Management LLC acquired a new position in Abbott Laboratories during the 4th quarter worth about $25,000. Purpose Unlimited Inc. acquired a new position in Abbott Laboratories during the 4th quarter worth about $25,000. Portfolio Resources Advisor Group Inc. bought a new stake in Abbott Laboratories during the 4th quarter worth about $26,000. Finally, Abound Financial LLC acquired a new stake in Abbott Laboratories in the 4th quarter valued at about $26,000. 75.18% of the stock is owned by institutional investors and hedge funds.

Trending Headlines about Abbott Laboratories

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: Abbott outperformed the market during the latest trading session, supported by continued investor interest in the diversified healthcare-products maker. Its shares are trading above both the 50-day and 200-day moving averages, indicating favorable near-term momentum. Abbott Exceeds Market Returns: Some Facts to Consider
• Positive Sentiment: Abbott’s latest reported quarter showed solid fundamentals: adjusted earnings exceeded consensus estimates, revenue surpassed expectations, and sales increased 13% year over year. Management’s 2026 earnings guidance remains consistent with analyst expectations, helping support the investment case.
• Neutral Sentiment: Industry research projects continued growth in cardiovascular ultrasound systems through 2030, driven by portable devices, artificial intelligence, 3D/Doppler imaging and remote diagnostics. The opportunity is broadly relevant to Abbott’s cardiovascular-device business, although the report primarily highlights GE HealthCare, Philips and Siemens Healthineers rather than announcing a specific Abbott development. Cardiovascular Ultrasound Systems Market Outlook
• Neutral Sentiment: Recent commentary notes that Abbott has lagged the healthcare sector over the past year, but analysts remain broadly optimistic about its long-term prospects. This creates a mixed backdrop: valuation and relative performance could restrain gains, while analyst confidence and business diversification provide support. Abbott Laboratories Stock: Is ABT Underperforming the Healthcare Sector?

Analysts Set New Price Targets

A number of brokerages have recently issued reports on ABT. Royal Bank Of Canada reiterated an "outperform" rating and set a $130.00 target price on shares of Abbott Laboratories in a research report on Friday, July 17th. UBS Group lowered their price target on shares of Abbott Laboratories from $135.00 to $125.00 and set a "buy" rating for the company in a report on Tuesday, July 28th. Wolfe Research upgraded shares of Abbott Laboratories from a "peer perform" rating to an "outperform" rating and set a $130.00 price objective for the company in a research report on Thursday, August 13th. BTIG Research upped their price objective on Abbott Laboratories from $131.00 to $134.00 and gave the stock a "buy" rating in a report on Friday, July 17th. Finally, The Goldman Sachs Group decreased their price objective on Abbott Laboratories from $121.00 to $113.00 and set a "buy" rating on the stock in a research report on Wednesday, May 27th. Three investment analysts have rated the stock with a Strong Buy rating, twenty have issued a Buy rating and four have given a Hold rating to the company's stock. According to data from MarketBeat, Abbott Laboratories has an average rating of "Moderate Buy" and a consensus price target of $119.50.

Abbott Laboratories Stock Up 1.5%

Shares of NYSE:ABT opened at $110.52 on Thursday. The company has a debt-to-equity ratio of 0.57, a current ratio of 1.38 and a quick ratio of 0.97. The stock has a market cap of $191.24 billion, a price-to-earnings ratio of 35.77, a P/E/G ratio of 2.02 and a beta of 0.59. The company has a 50 day moving average of $103.83 and a 200-day moving average of $100.09. Abbott Laboratories has a one year low of $81.97 and a one year high of $137.49.

Abbott Laboratories (NYSE:ABT - Get Free Report) last announced its quarterly earnings data on Thursday, July 16th. The healthcare product maker reported $1.31 earnings per share for the quarter, beating the consensus estimate of $1.28 by $0.03. Abbott Laboratories had a net margin of 11.65% and a return on equity of 17.69%. The business had revenue of $12.59 billion for the quarter, compared to analyst estimates of $12.52 billion. During the same period in the prior year, the business posted $1.26 earnings per share. Abbott Laboratories's revenue was up 13.0% compared to the same quarter last year. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. On average, sell-side analysts forecast that Abbott Laboratories will post 5.52 earnings per share for the current year.

Abbott Laboratories Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Monday, August 17th. Stockholders of record on Wednesday, July 15th were paid a $0.63 dividend. The ex-dividend date of this dividend was Wednesday, July 15th. This represents a $2.52 dividend on an annualized basis and a dividend yield of 2.3%. Abbott Laboratories's dividend payout ratio is 81.55%.

Abbott Laboratories Company Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.

Want to see what other hedge funds are holding ABT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abbott Laboratories (NYSE:ABT - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source